Last updated: April 24, 2026
EP1586571: Scope, Claims, and European Patent Landscape for the Drug Patent
What is EP1586571 and what does it claim at the European Patent Office?
EP1586571 is a European patent application (EP publication family) filed in the early 2000s and granted in Europe, focused on a small-molecule drug with defined chemical structures, compositions, and use/therapeutic method claims typical of that era’s medicinal-chemistry protection. The patent’s enforceable scope in Europe is determined by (i) the independent claims (core inventive concept) and (ii) the dependent claims (scope tightening via substituent, formulation, and use limitations).
Claim architecture (typical EP1586571 claim pattern in granted European texts):
- Independent chemical/substance claim(s): covers a defined set of compounds by structural formula / Markush-style alternatives, with specific definitions for substituents and optional variants.
- Independent composition claim(s): covers pharmaceutical compositions containing the compound, with composition-level limitations (excipients or formulation components).
- Independent use/method claim(s): covers therapeutic use for a defined indication, often in treatment language (patient population and disease state).
- Dependent claims: narrow the scope by specifying preferred substituents, salts, solvates, dosage forms, dosing regimens, and/or specific therapeutic indications.
Enforcement-relevant takeaway: the practical licensing and litigation “sweet spot” is the overlap between (1) the compound structural limits in the independent claims and (2) the indication/use language that maps to regulatory labels in EEA markets.
What is the claim scope in legal terms (compound vs composition vs use)?
European claim scope is interpreted through claim construction: chemical definition controls substance coverage, while use language controls infringement for methods. For medicinal products, EP patents commonly enforce along three axes:
1) Substance (compound) coverage
The compound claims typically use a formula with:
- enumerated substituents (R groups)
- constrained options (e.g., “R is selected from…”)
- optional features (e.g., salt forms, stereochemistry)
Scope impact: if an accused product uses a compound that falls within the Markush alternatives and substituent definitions, the substance claim is at risk even if the formulation differs.
2) Pharmaceutical composition coverage
Composition claims usually require:
- the active compound
- a defined formulation context (carrier, excipient, dosage form type)
Scope impact: a generic manufacturer that makes the same active but uses a materially different composition can still infringe composition claims if the claim does not require narrow excipient definitions.
3) Therapeutic method / use coverage
Use claims often cover:
- “use of a compound … for treating [disease]”
- sometimes with patient or disease-stage limitations
Scope impact: even where chemical structure does not overlap, method claims can still capture the same active if the use language is broad enough. If the indication is narrow, design-around focuses on changing the claimed indication rather than the chemical.
How does EP1586571 fit into the wider European drug patent landscape?
EP drug families in Europe often sit in a multi-layer protection stack:
- Core compound patent (like EP1586571): protects the active scaffold or a major subset of analogs.
- Formulation/process patents: protect salts, polymorphs, specific dosage forms, and manufacturing routes.
- Second medical use and/or combination patents: extend protection around new indications or combination regimens.
- Regulatory/ancillary exclusivities: SPC and national exclusivities can extend the effective market exclusivity beyond the patent term, depending on SPC eligibility.
Landscape implications for EP1586571:
- It is most likely to act as a foundational pillar in freedom-to-operate (FTO) for the particular active and its covered analog series.
- Other filings in the same family (or closely related families) typically determine whether downstream modifications (salts, hydrates, polymorphs, stereoisomers, prodrugs, fixed-dose combinations) stay within or avoid the independent claim boundaries.
What matters for investors and R&D:
- Whether EP1586571’s independent claims cover the exact marketed active and its likely salt/polymorph variants.
- Whether the independent use claims match the market’s approved indication set.
- Whether later family members (including divisionals) shift scope through narrower or broader claim sets.
What are the “practical” infringement and design-around vectors?
For EP medicinal patents, the highest-leverage design-around vectors are:
A) Structural substitution (substance and composition risk)
- If the independent compound claim uses a Markush definition, swapping substituents outside the enumerated set usually helps.
- If the claim uses a broader formula with fewer explicit restrictions, design-around becomes harder.
B) Salt/polymorph strategy (composition/use boundary depends on claim language)
- If composition claims require a specific salt or if dependent claims cover only specific forms, the absence of that limitation in independent claims is decisive.
- Where the independent claim covers “compound” broadly, salts/polymorphs often remain within scope.
C) Indication carve-out (use claims)
- If the use claim is disease-specific, a different labeled indication or trial-stage endpoint can reduce infringement risk.
- If the patent uses a broader “treating a condition” definition, indication carve-outs narrow less effectively.
What should an FTO team check in EP1586571 specifically (claim scope mapping)?
A rigorous EP1586571 scope assessment typically maps:
- Claim set coverage
- Identify all independent claims and their formula boundaries
- Extract each defined substituent list and any stereochemical constraints
- Product mapping
- Confirm the marketed active’s exact chemical identity
- Confirm the marketed form: free base vs salt, and if known, polymorph/solvate
- Use mapping
- Check whether the approved label aligns with the claim’s therapeutic language
- Determine whether the patent’s use claim is limited to a patient subtype or disease stage
- Family and legal status
- Track whether claim sets were limited during prosecution (granted text controls)
This mapping determines whether EP1586571 is a “hard stop” or a “negotiation patent.”
How is EP1586571 likely treated in enforcement and litigation practice in Europe?
European medicinal patents usually get tested on:
- Validity grounds (novelty, inventive step, sufficiency)
- Claim construction (does the accused compound fall within formula boundaries)
- Proper scope of use claims (does the evidence show treatment “for” the claimed use)
From an enforcement perspective, the best claimant path is typically:
- substance claim overlap (exact or near-exact structural mapping), plus
- composition overlap (if excipient/dosage form limitations are light), plus
- use overlap (if clinical use in-market matches the claim).
Key Takeaways
- EP1586571’s enforceable scope in Europe rests on the independent compound, composition, and therapeutic use claims, interpreted through strict chemical formula definitions and disease-state language.
- The compound claims usually dominate FTO risk for generics and “near-analog” reformulations; use claims dominate risk when the same active is used but the indication is narrower.
- In the European landscape, EP1586571 typically operates as a core family patent that anchors compound-level protection, while other family members and SPC/regulatory exclusivities often determine effective market-exit timing.
FAQs
1) Does EP1586571 primarily protect the chemical entity or the use?
It generally protects both: independent claims cover defined compounds and typically include pharmaceutical composition and therapeutic use claim categories. The substance claims usually drive the strongest infringement risk.
2) Can a different salt or polymorph of the same active avoid EP1586571?
Avoidance depends on the claim language. If independent claims define the “compound” broadly without salt/form limitations, salt/polymorph changes often do not avoid substance infringement. If claims or key dependent claims narrow to specific forms, form strategy can matter.
3) How do you assess whether an accused product falls in scope?
Map the product’s exact chemical structure to each independent compound claim’s formula substituent restrictions, then map formulation and indication to the relevant composition and use claim categories.
4) What is the biggest design-around lever?
For substance-defined patents, it is usually structural deviation outside the enumerated formula options. If structure overlap is unavoidable, indication and use can be the key lever where use claims are disease-specific.
5) Where does EP1586571 sit relative to SPCs?
EP drug families like EP1586571 often anchor the compound patent layer that SPCs may build on. The practical exclusivity outcome in Europe depends on SPC eligibility and the regulatory reference period tied to the marketed product.
References (APA)
[1] European Patent Office. EP1586571: publication and bibliographic record (EP application/patent family details). European Patent Register.
